Skip to main content
Sumitomo Pharma Co., Ltd. logo

Sumitomo Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 4506 ISIN · JP3495000006 LEI · 529900D60UKVYLJ2OJ79 T Manufacturing
Open in API
Filings indexed 94 across all filing types
Latest filing 2024-01-31 Regulatory Filings
Country JP Japan
Listing T 4506

About Sumitomo Pharma Co., Ltd.

https://www.sumitomo-pharma.com/

Sumitomo Pharma Co., Ltd. is a research and development-driven pharmaceutical company focused on creating innovative pharmaceuticals and healthcare solutions. The company's primary therapeutic areas are Psychiatry & Neurology and Oncology, with additional activities in diabetes, rare diseases, and women's health. A key aspect of its R&D strategy is the integration of established expertise in small molecule drug discovery with pioneering modalities such as regenerative medicine and cell therapy. The company's mission is to translate scientific innovation into real-world solutions to contribute to the betterment of healthcare and fuller lives for people worldwide, with a strategic business focus on Japan and the United States.

Recent filings

Filing Released Lang Actions
臨時報告書
Regulatory Filings Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) and is submitted to the Kanto Local Finance Bureau Director ('関東財務局長') based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act. The content details significant events affecting the company's financial condition, specifically mentioning the booking of business restructuring costs and foreign exchange gains, and their impact on the consolidated financial statements for the third quarter cumulative period of the fiscal year ending March 2024. This structure—a formal filing detailing a significant, non-periodic event outside of standard quarterly/annual reporting cycles—aligns best with the definition of a general regulatory filing or an extraordinary report. In the provided schema, 'Regulatory Filings' (RNS) is the most appropriate fallback for miscellaneous, non-standard regulatory disclosures that don't fit the specific categories like 10-K, ER, or IR. Given the Japanese regulatory context (Fifth No. 3 Form under the Cabinet Office Ordinance), RNS serves as the best fit among the options for a general, mandatory disclosure of a significant event.
2024-01-31 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act in Japan. It serves as a formal certification by the CEO regarding the accuracy of the quarterly report (204th term, 2nd quarter). Since it is a regulatory filing required by law to accompany financial reports and does not fit into the specific categories of financial statements or earnings releases, it is classified as a Regulatory Filing (RNS).
2023-11-02 Japanese
四半期報告書－第204期第2四半期(2023/07/01－2023/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan, as indicated by the header and the regulatory reference (Financial Instruments and Exchange Act). It contains detailed financial statements, management analysis (MDA), and segment reporting for the second quarter of the 204th fiscal period (April 1, 2023, to September 30, 2023). Since it is a comprehensive financial report for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2024
2023-11-02 Japanese
臨時報告書
Regulatory Filings Classification · 100% confidence The document is a 'Rinji Hokokusho' (Extraordinary Report) filed with the Kanto Local Finance Bureau in Japan. This type of filing is required under the Financial Instruments and Exchange Act when a company experiences significant events affecting its financial condition or business operations. Since it is a specific regulatory filing regarding material events (restructuring costs and foreign exchange gains) and does not fit into the other specific categories like 10-K, ER, or M&A, it is classified as a Regulatory Filing (RNS).
2023-10-31 Japanese
臨時報告書
Regulatory Filings Classification · 100% confidence The document is a 'Rinji Hokokusho' (Extraordinary Report) filed with the Kanto Local Finance Bureau in Japan. It details corporate restructuring involving the merger and dissolution of specific subsidiaries (Urovant Sciences, Enzyvant Therapeutics, etc.). In the context of Japanese regulatory filings, these reports are mandatory disclosures for significant corporate events. Since it does not fit into specific categories like M&A (which usually refers to external acquisitions) or Board changes, and is a formal regulatory filing required by the Financial Instruments and Exchange Act, it is classified as a Regulatory Filing (RNS).
2023-09-14 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act in Japan. It specifically confirms the accuracy of the contents of the Quarterly Report (Shihanki Hokokusho) for the first quarter of the 204th fiscal period. Since this is a regulatory filing confirming the accuracy of a report rather than the report itself, and it does not fit into the other specific categories like 10-K or IR, it falls under the general regulatory filing category.
2023-08-03 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.